Axsome Therapeutics, Inc. Insider Trading

AXSM

Last 12 months

Insiders sold $134M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Sep 2025.

Net open-market

−$134M

0 buys · 20 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Sep 2025

Sep 8, 2025

Get an email when AXSM's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 3	Mark L. Jacobson Chief Operating Officer	Sold10b5-1 plan	10,000	$208.65	$2.09M	100%	Form 4
Aug 5 – 6	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan 2 parts	49,664	$212.19 average	$10.5M	0.7%	Form 4
Jul 1	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan	49,666	$240.25	$11.9M	0.7%	Form 4
Jun 10 – 11	Roger Jeffs Director	Sold10b5-1 plan 2 parts	572	$247.65 average	142K	1.0%	Form 4
Jun 9 – 10	Susan Mahony Director	Sold10b5-1 plan 2 parts	600	$241.70 average	145K	42%	Form 4
Jun 10	Mark Coleman Director	Sold10b5-1 plan	643	$249.00	160K	0.1%	Form 4
Jun 9	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan	49,670	$241.01	$12M	0.7%	Form 4
Jun 9	Nick Pizzie Chief Financial Officer	Sold10b5-1 plan	33,000	$240.09	$7.92M	43%	Form 4
May 29 – Jun 2	Mark Coleman Director	Sold10b5-1 plan 3 parts	17,537	$229.20 average	$4.02M	3.9%	Form 4
May 4 – 5	Mark L. Jacobson Chief Operating Officer	Sold10b5-1 plan 2 parts	4,750	$227.95 average	$1.08M	100%	Form 4
Apr 22	Ari Maizel Chief Commercial Officer	Sold10b5-1 plan	7,500	$182.42	$1.37M	100%	Form 4
Feb 26	Mark Coleman Director	Sold10b5-1 plan	25,000	$161.11	$4.03M	5.3%	Form 4
Feb 26	Mark L. Jacobson Chief Operating Officer	Sold10b5-1 plan	35,378	$161.88	$5.73M	100%	Form 4
Feb 2	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan	32,410	$185.60	$6.02M	0.4%	Form 4
Jan 22	Nick Pizzie Chief Financial Officer	Sold10b5-1 plan	12,000	$187.92	$2.26M	22%	Form 4
Jan 21	Ari Maizel Chief Commercial Officer	Sold10b5-1 plan	7,500	$184.44	$1.38M	100%	Form 4
Jan 5 – 7	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan 3 parts	139,414	$171.30 average	$23.9M	1.9%	Form 4
Dec 31, 2025	Mark E Saad Director	Sold10b5-1 plan 2 parts	37,577	$165.18 average	$6.21M	78%	Form 4
Dec 2, 2025 – Dec 4, 2025	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan 3 parts	79,973	$145.66 average	$11.6M	1.1%	Form 4
Nov 3, 2025 – Nov 5, 2025	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan 3 parts	163,939	$133.07 average	$21.8M	2.2%	Form 4
Oct 6, 2025 – Oct 8, 2025	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan 3 parts	45,384	$119.38 average	$5.42M	0.6%	Form 4
Sep 22, 2025	Mark L. Jacobson Chief Operating Officer	Sold10b5-1 plan	10,000	$115.96	$1.16M	100%	Form 4
Sep 16, 2025	Mark L. Jacobson Chief Operating Officer	Sold10b5-1 plan 2 parts	45,783	$114.48 average	$5.24M	100%	Form 4
Sep 12, 2025 – Sep 16, 2025	Herriot Tabuteau Chief Executive Officer	Sold10b5-1 plan 3 parts	62,880	$117.08 average	$7.36M	0.8%	Form 4
Sep 8, 2025	Mark Coleman Director	Bought 3 parts	1,575	$127.28 average	200K	0.3%	Form 4
Sep 5, 2025	Mark E Saad Director	Sold10b5-1 plan	9,127	$125.07	$1.14M	47%	Form 4
Sep 2, 2025	Roger Jeffs Director	Sold10b5-1 plan	13,464	$123.68	$1.67M	19%	Form 4
Aug 27, 2025 – Aug 29, 2025	Roger Jeffs Director	Sold10b5-1 plan 3 parts	60,000	$121.72 average	$7.3M	46%	Form 4
Aug 22, 2025 – Aug 26, 2025	Roger Jeffs Director	Sold10b5-1 plan 2 parts	36,694	$120.05 average	$4.41M	22%	Form 4
Jun 20, 2025 – Jun 23, 2025	Hunter R. Murdock General Counsel	Sold10b5-1 plan 2 parts	13,514	$101.42 average	$1.37M	100%	Form 4
Jun 16, 2025 – Jun 18, 2025	Hunter R. Murdock General Counsel	Sold10b5-1 plan 3 parts	22,500	$101.19 average	$2.28M	100%	Form 4
Jun 9, 2025	Mark L. Jacobson Chief Operating Officer	Sold10b5-1 plan	25,000	$110.44	$2.76M	81%	Form 4
May 27, 2025 – May 28, 2025	Mark Coleman Director	Sold10b5-1 plan 2 parts	7,500	$104.45 average	783K	1.6%	Form 4
May 27, 2025 – May 28, 2025	Mark L. Jacobson Chief Operating Officer	Sold10b5-1 plan 2 parts	40,673	$104.07 average	$4.23M	88%	Form 4
May 20, 2025	Mark Coleman Director	SoldNo plan	3,000	$107.49	322K	0.7%	Form 4
Feb 13, 2025 – Feb 14, 2025	Nick Pizzie Chief Financial Officer	Sold10b5-1 plan 2 parts	15,000	$130.10 average	$1.95M	26%	Form 4

Sep 310b5-1 plan
Mark L. Jacobson
Chief Operating Officer · sold 10,000 at $208.65
$2.09M
100% of stake
Aug 5 – 610b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 49,664 at avg $212.19
$10.5M
0.7% of stake
Jul 110b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 49,666 at $240.25
$11.9M
0.7% of stake
Jun 10 – 1110b5-1 plan
Roger Jeffs
Director · sold 572 at avg $247.65
142K
1.0% of stake
Jun 9 – 1010b5-1 plan
Susan Mahony
Director · sold 600 at avg $241.70
145K
42% of stake
Jun 1010b5-1 plan
Mark Coleman
Director · sold 643 at $249.00
160K
0.1% of stake
Jun 910b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 49,670 at $241.01
$12M
0.7% of stake
Jun 910b5-1 plan
Nick Pizzie
Chief Financial Officer · sold 33,000 at $240.09
$7.92M
43% of stake
May 29 – Jun 210b5-1 plan
Mark Coleman
Director · sold 17,537 at avg $229.20
$4.02M
3.9% of stake
May 4 – 510b5-1 plan
Mark L. Jacobson
Chief Operating Officer · sold 4,750 at avg $227.95
$1.08M
100% of stake
Apr 2210b5-1 plan
Ari Maizel
Chief Commercial Officer · sold 7,500 at $182.42
$1.37M
100% of stake
Feb 2610b5-1 plan
Mark Coleman
Director · sold 25,000 at $161.11
$4.03M
5.3% of stake
Feb 2610b5-1 plan
Mark L. Jacobson
Chief Operating Officer · sold 35,378 at $161.88
$5.73M
100% of stake
Feb 210b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 32,410 at $185.60
$6.02M
0.4% of stake
Jan 2210b5-1 plan
Nick Pizzie
Chief Financial Officer · sold 12,000 at $187.92
$2.26M
22% of stake
Jan 2110b5-1 plan
Ari Maizel
Chief Commercial Officer · sold 7,500 at $184.44
$1.38M
100% of stake
Jan 5 – 710b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 139,414 at avg $171.30
$23.9M
1.9% of stake
Dec 31, 202510b5-1 plan
Mark E Saad
Director · sold 37,577 at avg $165.18
$6.21M
78% of stake
Dec 2, 2025 – Dec 4, 202510b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 79,973 at avg $145.66
$11.6M
1.1% of stake
Nov 3, 2025 – Nov 5, 202510b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 163,939 at avg $133.07
$21.8M
2.2% of stake
Oct 6, 2025 – Oct 8, 202510b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 45,384 at avg $119.38
$5.42M
0.6% of stake
Sep 22, 202510b5-1 plan
Mark L. Jacobson
Chief Operating Officer · sold 10,000 at $115.96
$1.16M
100% of stake
Sep 16, 202510b5-1 plan
Mark L. Jacobson
Chief Operating Officer · sold 45,783 at avg $114.48
$5.24M
100% of stake
Sep 12, 2025 – Sep 16, 202510b5-1 plan
Herriot Tabuteau
Chief Executive Officer · sold 62,880 at avg $117.08
$7.36M
0.8% of stake
Sep 8, 2025
Mark Coleman
Director · bought 1,575 at avg $127.28
200K
0.3% of stake
Sep 5, 202510b5-1 plan
Mark E Saad
Director · sold 9,127 at $125.07
$1.14M
47% of stake
Sep 2, 202510b5-1 plan
Roger Jeffs
Director · sold 13,464 at $123.68
$1.67M
19% of stake
Aug 27, 2025 – Aug 29, 202510b5-1 plan
Roger Jeffs
Director · sold 60,000 at avg $121.72
$7.3M
46% of stake
Aug 22, 2025 – Aug 26, 202510b5-1 plan
Roger Jeffs
Director · sold 36,694 at avg $120.05
$4.41M
22% of stake
Jun 20, 2025 – Jun 23, 202510b5-1 plan
Hunter R. Murdock
General Counsel · sold 13,514 at avg $101.42
$1.37M
100% of stake
Jun 16, 2025 – Jun 18, 202510b5-1 plan
Hunter R. Murdock
General Counsel · sold 22,500 at avg $101.19
$2.28M
100% of stake
Jun 9, 202510b5-1 plan
Mark L. Jacobson
Chief Operating Officer · sold 25,000 at $110.44
$2.76M
81% of stake
May 27, 2025 – May 28, 202510b5-1 plan
Mark Coleman
Director · sold 7,500 at avg $104.45
783K
1.6% of stake
May 27, 2025 – May 28, 202510b5-1 plan
Mark L. Jacobson
Chief Operating Officer · sold 40,673 at avg $104.07
$4.23M
88% of stake
May 20, 2025No plan
Mark Coleman
Director · sold 3,000 at $107.49
322K
0.7% of stake
Feb 13, 2025 – Feb 14, 202510b5-1 plan
Nick Pizzie
Chief Financial Officer · sold 15,000 at avg $130.10
$1.95M
26% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AXSM, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AXSM

CompareIntrinsic value

SUPNSupernus Pharmaceuticals Inc.

$28.21+0.21%44

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

CORTCorcept Therapeutics Incorporated

$77.59-5.30%56

COLLCollegium Pharmaceutical Inc.

$23.56-0.72%98

TGTXTG Therapeutics, Inc.

$61.63+1.45%57

BBIOBridgeBio Pharma, Inc.

$77.89+5.21%30

KNSAKiniksa Pharmaceuticals International, plc

$96.12+3.03%71

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

Held by ETFs

AXSM is in 91 US ETFs. The largest of them, with AXSM's weight in each:

Spot a number that looks wrong? Check it in AXSM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AXSM

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.